Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bukwang Pharmaceutical
This is a two-part, Phase 2, double-blind, placebo-controlled, randomized, multicentre study.
Subjects with a diagnosis of PD and dyskinesias in PD will complete a Screening Visit to assess eligibility to participate in the study.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Is able to read, understand, and provide written, dated informed consent prior to Screening Visit.
Is male or female, between 18 and 85 years of age at Screening Visit.
Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria
Has experienced dyskinesia
Has stable peak-effect dyskinesia
Has more than one hour of "ON" time with troublesome dyskinesia
You may not be if
Has undergone surgery for the treatment of PD
Has a current diagnosis of Substance Use
Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses
Has current seizure disorders requiring treatment with anticonvulsants.
Other criteria related to other medical conditions to be referred to the protocol.
Clareo Health | Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
